After India, Novo Nordisk cuts WeGovy price in China on generics challenge
Novo Nordisk's patent on WeGovy's active ingredient semaglutide is expiring in 2026.
Novo Nordisk's patent on WeGovy's active ingredient semaglutide is expiring in 2026.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
